Intracarotid Recombinant Tissue Plasminogen Activator in Acute Carotid Artery Territory Stroke
Our previous intravenous, double-blind, placebo-controlled trial of recombinant tissue plasminogen activator (rt-PA)  and other intravenous rt-PA trials [2–4] indicated that systemic administration of rt-PA was safe and effective in treating acute carotid artery territory embolic stroke. However, the recanalization efficacy demonstrated in those trials [1–4] was limited; recanalization frequency was at most 50%. Local intraarterial infusion is assumed to be safer and more effective than intravenous infusion by reduction of systemic side effects and increase of recanalization. To examine this assumption, we conducted an intraarterial rt-PA trial. We report here an interim analysis of our ongoing intracarotid trial, and the results are compared with those in our intravenous trial .
KeywordsInternal Carotid Artery Acute Ischemic Stroke Tissue Plasminogen Activator Hemorrhagic Transformation Recombinant Tissue Plasminogen Activator
Unable to display preview. Download preview PDF.
- 2.del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Albert MJ, Zivin J, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kace CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedCrossRefGoogle Scholar
- 4.Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W (eds) Thrombolytic therapy in acute ischemic stroke II. Springer, Berlin Heidelberg New York, pp 59–65CrossRefGoogle Scholar